Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Teva is offering lapatinib tablets, which is the generic of Tykerb. [Read more: Teva, mAbxience expand partnership for ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients ...

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma ...